


A COMPARATIVE EVALUATION OF THE LONG-TERM EFFECTIVENESS OF GUSELKUMAB AND RISANKIZUMAB IN THE CLINICAL MANAGEMENT OF PLAQUE PSORIASIS

M. RODRIGUEZ GOICOECHEA¹, L. GUTIÉRREZ LUCENA¹, A.J. MORENO LOPEZ¹, S. CANO DOMINGUEZ², C. GARRIDO COLMENERO³, F.G. MORENO SUAREZ³, M. OCAÑA CANO³, P. ACEITUNO³, E. TEJEDOR TEJADA⁴, F. HORNO UREÑA¹.

1 HOSPITALARY COMPLEX OF JAÉN, HOSPITAL PHARMACY, JAÉN, SPAIN. 2 HOSPITALARY COMPLEX OF GRANADA, HOSPITAL PHARMACY, GRANADA, SPAIN. 3 HOSPITALARY COMPLEX OF JAÉN, DERMATOLOGY, JAÉN, SPAIN. 4 CLINIC HOSPITAL OF BARCELONA, HOSPITAL PHARMACY, BARCELONA, SPAIN.

Background and importance

Anti-interleukin 23 drugs were approved in the last 6 years. The absence of long-term comparison between alternatives such as risankizumab or guselkumab needs to be fulfilled.



Aim and objectives

To evaluate the effectiveness through indirect comparisons of risankizumab and guselkumab in plaque psoriasis long-term treatment.

Material and methods

Multicentric, retrospective and observational study. Comparison made with plaque psoriasis patients with active treatment with risankizumab or guselkumab till September 2023 overcoming 52 weeks of treatment. Demographic (sex, age) and clinical (psoriasis area severity index (PASI) at baseline and in subsequent dermatology controls, PASI clearance (PASI 90 and PASI100)) data collected. Comparison made through PASI90/PASI100 and PASI reduction.

Results

110 patients recruited for the study, with 35.5% of them being female and with an average age of 51.7 years. Initial PASI score was 9.46 for the 46 patients treated with guselkumab, and 8.04 for the 64 patients treated with risankizumab. The results are shown in the next table:

Patients (N)	PASI	Averaged weeks	PASI90	PASI100
46 (guselkumab)	1,12	62	60,8%	56,5%
64 (risankizumab)	0,88	63	68,75%	62,5%
Patients (N)	PASI	Averaged weeks	PASI90	PASI100
23 (guselkumab)	0,94	114	69,5%	65,2%
30 (risankizumab)	0,89	110	63,3%	46,6%
Patients (N)	PASI	Averaged weeks	PASI90	PASI100
15 (guselkumab)	2,61	150	60%	60%
18 (risankizumab)	0,7	136	72,2%	50%



4CPS-217. L04
IMMUNOSUPPRESSANTS

Conclusion and relevance

Both molecules offer highly positive long-term results, particularly valued by patients with plaque psoriasis, although guselkumab seems to maintain a slightly greater full clearance.

References and/or acknowledgements

Artificial intelligence tool utilised to translate texts.